Enzo Biochem, Inc.  

(Public, NYSE:ENZ)   Watch this stock  
Find more results for ENZ
5.14
+0.03 (0.59%)
Oct 30 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 5.07 - 5.18
52 week 2.27 - 6.13
Open 5.10
Vol / Avg. 0.00/199,968.00
Mkt cap 227.42M
P/E     -
Div/yield     -
EPS -0.23
Shares 44.50M
Beta 2.07
Inst. own 44%
Oct 10, 2014
Q4 2014 Enzo Biochem Inc Earnings Call - Webcast
Oct 9, 2014
Q4 2014 Enzo Biochem Inc Earnings Release
Sep 18, 2014
Enzo Biochem Inc at Craig-Hallum Alpha Select Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '14) 2014
Net profit margin -12.72% -10.40%
Operating margin -12.26% -10.61%
EBITD margin - -9.70%
Return on average assets -20.03% -16.17%
Return on average equity -33.95% -28.07%
Employees 433 -
CDP Score - -

Address

60 EXECUTIVE BLVD
FARMINGDALE, NY 11735
United States - Map
+1-516-7555500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Enzo Biochem, Inc. (Enzo), is an integrated life sciences and biotechnology company. Enzo has three segments: Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics. Enzo focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community. The Company has developed a portfolio of technologies with a variety of research, diagnostic and therapeutic applications. Enzo Clinical Labs segment is a regional clinical laboratory serving the New York, New Jersey and Eastern Pennsylvania medical communities. The Company's Enzo Life Sciences manufactures, develops and markets products and tools to life sciences, drug development and clinical research customers world-wide. The Company's Enzo Therapeutics segment is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.

Officers and directors

Barry W. Weiner President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elazar Rabbani Ph.D. Chairman of the Board, Chief Executive Officer, Secretary
Age: 70
Bio & Compensation  - Reuters
James O'Brien Senior Vice President - Finance
Bio & Compensation  - Reuters
Herbert B. Bass Vice President - Finance
Age: 64
Bio & Compensation  - Reuters
Paul C. O'Brien Vice President - Global Human Resources
Age: 51
Bio & Compensation  - Reuters
David C. Goldberg Vice President - Corporate Development; Interim General Manager of Enzo Clinical Labs
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Bernard L. Kasten Jr., M.D. Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Gregory M. Bortz Independent Director
Age: 44
Bio & Compensation  - Reuters
Dov Perlysky Independent Director
Age: 51
Bio & Compensation  - Reuters